Alkahest is developing therapies derived from blood and its components with a focus to improve vitality and function into old age.
Alkahest – developing therapies derived from blood
Age is the major risk factor for many of the leading causes of death in the world, including heart disease, cancer, stroke, and dementia. Old age is accompanied by a precipitous decline in brain function and more than a third of people 85 years and older suffer from Alzheimer’s disease and related dementias. Alkahest focuses on improved vitality and function into old age to live the fullest life possible. A major hallmark of aging is that regenerative properties significantly decline in most tissues. Recent data demonstrated that the age-associated impairment of cell function is induced to a significant extent by the molecular composition of the surrounding milieu rather than by cell specific changes alone. Alkahest is committed to building the leading portfolio of treatments that extend life quality and address age-related conditions, based on naturally occurring proteins and factors derived from human plasma.
Alkahest is developing therapies derived from blood and its components with a focus to improve vitality and function into old age. Alkahest is working on treatments for diseases of aging, with an emphasis on cognitive dysfunction and dementia, which are key medical challenges of our generation. Alkahest’s pioneering research has demonstrated that factors in young plasma are able to reverse brain deficits in preclinical models relevant to normal aging and Alzheimer’s disease. Conversely, inhibition of factors that are present in old plasma can improve brain functions in preclinical models of age-related cognitive decline. Alkahest is conducting clinical studies in patients with different types of dementia and other neurodegenerative diseases.
Alkahest is a private biotech company headquartered in San Carlos, CA (USA). Management Team is composed by Karoly Nikolich, Stephen Peroutka, Steven Braithwaite, Joseph McCracken and Tammy Kent. Board of Directors is composed by Karoly Nikolich, David Bell, Thomas Glanzmann, Joseph McCracken and Tony Wyss-Coray. In March of 2015 Alkahest entered into a strategic partnership with Grifols, in which Grifols made a major equity investment in Alkahest and Alkahest agreed to work with Grifols to develop novel plasma-based products for the treatment of cognitive decline in aging and disorders of the central nervous system, including Alzheimer’s Disease. Grifols, established in 1940, operates in more than 100 countries worldwide, employs more than 14,000 employees, and is a leader in the development and production of plasma-derived medicines, thus being a powerful partner for Alkahest.
More about Alkahest : www.alkahest.com